1. Home
  2. ADC vs CYTK Comparison

ADC vs CYTK Comparison

Compare ADC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agree Realty Corporation

ADC

Agree Realty Corporation

HOLD

Current Price

$71.19

Market Cap

8.0B

Sector

Real Estate

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$64.71

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADC
CYTK
Founded
1971
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
8.0B
IPO Year
1994
2004

Fundamental Metrics

Financial Performance
Metric
ADC
CYTK
Price
$71.19
$64.71
Analyst Decision
Buy
Strong Buy
Analyst Count
12
16
Target Price
$80.65
$84.81
AVG Volume (30 Days)
1.4M
1.8M
Earning Date
02-10-2026
02-26-2026
Dividend Yield
4.35%
N/A
EPS Growth
N/A
N/A
EPS
1.71
N/A
Revenue
$688,643,000.00
$87,211,000.00
Revenue This Year
$17.19
$341.94
Revenue Next Year
$11.19
$75.44
P/E Ratio
$42.19
N/A
Revenue Growth
14.67
2609.26
52 Week Low
$68.98
$29.31
52 Week High
$79.65
$70.98

Technical Indicators

Market Signals
Indicator
ADC
CYTK
Relative Strength Index (RSI) 42.88 52.69
Support Level $70.77 $62.13
Resistance Level $73.06 $65.88
Average True Range (ATR) 1.22 2.46
MACD -0.04 0.08
Stochastic Oscillator 11.47 73.16

Price Performance

Historical Comparison
ADC
CYTK

About ADC Agree Realty Corporation

Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: